Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1197-1204

  Okui, Tatsuo ^a   Shimo, Tsuyoshi ^a   Hassan, Nur Mohammad Monsur ^a   Fukazawa, Takuya ^b   Kurio, Naito ^a   Takaoka, Munenori ^b   Naomoto, Yoshio ^c   Sasaki, Akira ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c NONE

Author keywords

HSP90 inhibitor; NVP AUY922; Oral squamous cell carcinoma

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; PROTEIN S6; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; ISOXAZOLES; MANDIBULAR NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; RECEPTOR, ERBB-2; RESORCINOLS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956150123     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hunter KD, Parkinson EK and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135, 2005. (Pubitemid 40220338)
2. Haddad RI and Shin DM: Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154, 2008.
3. Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC and Huang TS: Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J Biol Chem 285: 25458-25466, 2010.
4. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI and Rosen N: 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993, 2002. (Pubitemid 34517631)
5. Lattouf JB, Srinivasan R, Pinto PA, Linehan WM and Neckers L: Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Pract Urol 3: 590-601, 2006. (Pubitemid 44698094)
6. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chene P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C and Jensen MR: Preclinical antitumor activity of the orally available heat-shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 9: 906-919, 2010.
7. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S and Anderson KC: SNX-2112, a selective HSP90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-855, 2009.
8. Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC and Ghobrial IM: Targeting Akt and heat-shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res 14: 865-874, 2008. (Pubitemid 351231171)
9. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L and Workman P: NVP-AUY922: a novel heat-shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860, 2008. (Pubitemid 351556284)
10. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C and Chene P: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10: R33, 2008.
11. Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, McLarty J, Lurie A, Milligan EJ and Nathan CO: Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 120: 1159-1165, 2010.
12. Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA, MacDougall J, Ge J, Ali JA, Palombella VJ, Normant E, Adams J and Fritz CC: Hsp90 (heat-shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J Biol Chem 285: 39835-39843, 2010.
13. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410, 2003. (Pubitemid 37187270)
14. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A and Workman P: Acquired resistance to 17-allylamino-17- demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 69: 1966-1975, 2009.
15. Okui T, Shimo T, Fukazawa T, Kurio N, Hassan NM, Honami T, Takaoka M, Naomoto Y and Sasaki A: Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Mol Cancer Ther 9: 2960-2969, 2010.
16. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A and Takigawa M: Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21: 1045-1059, 2006. (Pubitemid 43962833)
17. Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549, 2010.
18. Porter JR, Fritz CC and Depew KM: Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14: 412-420, 2010.
19. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P and Wright L: 4,5-Diarylisoxazole HSP90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218, 2008.
20. Karkoulis PK, Stravopodis DJ, Margaritis LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces down-regulation of critical HSP90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 10: 481, 2010.
21. Papavasileiou D, Tosios K, Christopoulos P, Goutas N and Vlachodimitropoulos D: HER-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not HER-2 amplification. Head Neck Pathol 3: 263-270, 2009.
22. Silva SD, Perez DE, Alves FA, Nishimoto IN, Pinto CA, Kowalski LP and Graner E: ErbB2 and fatty acid synthase (FAS) expression in 102 squamous cell carcinomas of the tongue: correlation with clinical outcomes. Oral Oncol 44: 484-490, 2008. (Pubitemid 351608619)
23. Matta A and Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 1: 6, 2009.
24. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW and Ogilvie D: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 16: 1159-1169, 2010.
25. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G and Workman P: Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9: 1219-1233, 2010.
26. Kim HL, Cassone M, Otvos L Jr. and Vogiatzi P: HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone HSP90: therapeutic considerations. Cancer Biol Ther 7: 10-14, 2008. (Pubitemid 351590444)
27. Liu YV and Semenza GL: RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 6: 656-659, 2007.
28. Staufer K and Stoeltzing O: Implication of heat-shock protein 90 (HSP90) in tumor angiogenesis: A molecular target for anti-angiogenic therapy? Curr Cancer Drug Targets 10: 890-897, 2010.